“Despite predictions that our actions would increase rates and destabilize markets, the opposite has happened,” says CMS Administrator Seema Verma.
Evofem Biosciences is on the cusp of releasing a revolutionary birth control product. But before the FDA gives its approval, this small biopharma has to navigate two very different clinical trials.
A discussion regarding the challenging decisions Pfenex made in the past year regarding its biosimilar pipeline and the company’s efforts getting its teriparatide follow-on ready for the 505(b)(2) pathway.
The larger BioHealth Capital Region, of which the I-270 biotech corridor is a part, currently ranks as the fifth largest biotech hub in the U.S. with 39,000 people employed by the industry.
Falsified medicines are a critical challenge to the safety of patients and to the reputation of the pharmaceutical industry. Serialization is a major step toward drug safety across the EU but has brought with it a set of challenges that national authorities and companies are tackling.
Rob Wright shares a personal anecdote about his experience of breaking into the biopharmaceutical industry, along with insight from three biopharma CEOs on what can be done to save the industry’s
Liz Barrett, CEO of Novartis Oncology, discusses taking a proactive approach toward mentoring tomorrow’s leaders.
Novartis Oncology CEO, Liz Barrett, on career advancement and family, a common challenge for women in the workplace.